Payment overview · 2025
General Payments
$1,586.74
82 reported records · 15 companies
Healthcare provider profile · identity verified
James H. Esther, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Rheumatology · CHESTERFIELD, MO · NPI 1609838309
Verified facts
What the public records show
CMS Open Payments records show James H. Esther, M.D. received $1,586.74 in general payments during 2025 across 82 reported records.
Amgen Inc. accounted for 15.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Arexvy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $250.12 | 15.8% | 19 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $244.06 | 15.4% | 15 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $237.62 | 15.0% | 11 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $198.30 | 12.5% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $185.24 | 11.7% | 8 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $97.06 | 6.1% | 6 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $91.80 | 5.8% | 3 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $72.98 | 4.6% | 3 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $58.74 | 3.7% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $48.21 | 3.0% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $31.51 | 2.0% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $21.09 | 1.3% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.78 | 1.2% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $17.22 | 1.1% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $14.01 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,586.74 | 82 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SAPHNELO Normalized: saphnelo |
Biological | AstraZeneca Pharmaceuticals LP | $165.76 | 3 | 2025 |
Source payment records
|
|||||
| XELJANZ Normalized: xeljanz |
Drug | PFIZER INC. | $156.73 | 10 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $151.52 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $135.43 | 1 | 2025 |
Source payment records
|
|||||
| COSENTYX Normalized: cosentyx |
Drug | Novartis Pharmaceuticals Corporation | $123.21 | 5 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $114.41 | 6 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $91.80 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $82.99 | 8 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $82.99 | 8 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $78.57 | 6 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $72.98 | 3 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $72.38 | 3 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $65.24 | 4 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $60.77 | 2 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $58.74 | 3 | 2025 |
Source payment records
|
|||||
| BENLYSTA Normalized: benlysta |
Biological | GlaxoSmithKline, LLC. | $51.26 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $48.21 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $45.80 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $45.80 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $42.87 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $39.12 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $31.51 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $29.79 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $29.79 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $25.10 | 1 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $23.32 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $21.09 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $21.08 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $19.33 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.78 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.78 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.22 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $17.13 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $14.01 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $9.22 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 26 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 46 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
26 | 26 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
44 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 558 | 152 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 406 | 113 |
| Levothyroxine Sodium | Levothyroxine Sodium | 389 | 96 |
| Prednisone | Prednisone | 313 | 82 |
| Amlodipine Besylate | Amlodipine Besylate | 254 | 79 |
| Allopurinol | Allopurinol | 246 | 73 |
| Alprazolam | Alprazolam | 230 | 64 |
| Lisinopril | Lisinopril | 214 | 58 |
| Simvastatin | Simvastatin | 208 | 51 |
| Losartan Potassium | Losartan Potassium | 205 | 58 |
| Tramadol Hcl | Tramadol Hcl | 201 | 68 |
| Sulfasalazine | Sulfasalazine | 185 | 56 |
| Hydrochlorothiazide | Hydrochlorothiazide | 133 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 125 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 122 | 26 |
| Metformin Hcl | Metformin Hcl | 120 | 32 |
| Meloxicam | Meloxicam | 119 | 33 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 117 | 27 |
| Methotrexate | Methotrexate Sodium | 114 | 39 |
| Metoprolol Succinate | Metoprolol Succinate | 114 | 33 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 110 | 26 |
| Omeprazole | Omeprazole | 95 | 24 |
| Potassium Chloride | Potassium Chloride | 94 | 25 |
| Leflunomide | Leflunomide | 85 | 23 |
| Celecoxib | Celecoxib | 84 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 84 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 77 | 19 |
| Atenolol | Atenolol | 76 | 19 |
| Trazodone Hcl | Trazodone Hcl | 76 | 22 |
| Sertraline Hcl | Sertraline Hcl | 71 | 16 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 67 | 14 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 67 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 66 | 15 |
| Gabapentin | Gabapentin | 65 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 63 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 55 | 13 |
| Famotidine | Famotidine | 52 | 20 |
| Irbesartan | Irbesartan | 49 | 15 |
| Furosemide | Furosemide | 48 | 16 |
| Methylprednisolone | Methylprednisolone | 48 | 41 |
| Diazepam | Diazepam | 47 | 12 |
| Synthroid | Levothyroxine Sodium | 46 | suppressed |
| Eliquis | Apixaban | 44 | 13 |
| Folic Acid | Folic Acid | 39 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 39 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 37 | suppressed |
| Pregabalin | Pregabalin | 35 | 11 |
| Valacyclovir | Valacyclovir Hcl | 35 | suppressed |
| Azithromycin | Azithromycin | 34 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 33 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 32 | suppressed |
| Fenofibrate | Fenofibrate | 31 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 14 |
| Spironolactone | Spironolactone | 28 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 27 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 26 | 26 |
| Carvedilol | Carvedilol | 25 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 25 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 22 | 12 |
| Lansoprazole | Lansoprazole | 22 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 22 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 19 |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Clonazepam | Clonazepam | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 12 |
| Lorazepam | Lorazepam | 13 | suppressed |
| Avapro | Irbesartan | 12 | suppressed |
| Ezetimibe | Ezetimibe | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Sulfasalazine Dr | Sulfasalazine | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,586.74 · 82 records | Amgen Inc. | AIRSUPRA, AREXVY, BENLYSTA, Bimzelx, COMIRNATY, COSENTYX, EVENITY, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FREESTYLE LIBRE 3, GEMTESA, KRYSTEXXA, LEQVIO, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, PREVNAR 20, PROLIA, PURIFIED CORTROPHIN GEL, QULIPTA, REPATHA, RINVOQ, Rybelsus, SAPHNELO, SHINGRIX, SKYRIZI, SYNTHROID, TAVNEOS, TREMFYA, UBRELVY, VOQUEZNA, XELJANZ, XIFAXAN, ZAVZPRET | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error